Vanda Pharmaceuticals Stock Today
| VNDA Stock | USD 5.19 0.21 4.22% |
Performance0 of 100
| Odds Of DistressLess than 1
|
Vanda Pharmaceuticals is trading at 5.19 as of the 28th of November 2024, a 4.22 percent increase since the beginning of the trading day. The stock's open price was 4.98. Vanda Pharmaceuticals has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Vanda Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of April 2006 | Category Healthcare | Classification Health Care |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. The company has 58.31 M outstanding shares of which 3.74 M shares are at this time shorted by private and institutional investors with about 5.23 trading days to cover. More on Vanda Pharmaceuticals
Moving against Vanda Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vanda Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Timothy Williams | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVanda Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vanda Pharmaceuticals' financial leverage. It provides some insight into what part of Vanda Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vanda Pharmaceuticals (VNDA) is traded on NASDAQ Exchange in USA. It is located in 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037 and employs 203 people. Vanda Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 314.86 M. Vanda Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 58.31 M outstanding shares of which 3.74 M shares are at this time shorted by private and institutional investors with about 5.23 trading days to cover.
Vanda Pharmaceuticals currently holds about 440.86 M in cash with 12.8 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Vanda Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationVanda Pharmaceuticals shows a total of 58.31 Million outstanding shares. The majority of Vanda Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vanda Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vanda Pharmaceuticals. Please pay attention to any change in the institutional holdings of Vanda Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vanda Ownership Details
Vanda Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Prudential Financial Inc | 2024-09-30 | 776.8 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 725.4 K | |
| Federated Hermes Inc | 2024-09-30 | 716.8 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 596.2 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 559.8 K | |
| Nuveen Asset Management, Llc | 2024-06-30 | 526.8 K | |
| Northern Trust Corp | 2024-09-30 | 501.2 K | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 419.5 K | |
| Krensavage Asset Management, Llc | 2024-09-30 | 414.7 K | |
| Blackrock Inc | 2024-06-30 | 8.1 M | |
| Renaissance Technologies Corp | 2024-09-30 | 4 M |
Vanda Pharmaceuticals Historical Income Statement
Vanda Stock Against Markets
Vanda Pharmaceuticals Corporate Management
| Scott Howell | Chief Officer | Profile | |
| Mihael MD | President, Founder | Profile | |
| Kevin Moran | CFO VP | Profile | |
| Elizabeth Every | Head Affairs | Profile | |
| Joakim Wijkstrom | Chief Marketing Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vanda Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (0.19) | Revenue Per Share 3.293 | Quarterly Revenue Growth 0.228 | Return On Assets (0.04) |
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.